SEQUOIA trial: Zanubrutinib + venetoclax in treatment-naïve patients with CLL/SLL

In this interview, Paolo Ghia shares preliminary outcomes from Arm D of the phase III SEQUOIA (NCT03336333) study of patients with del(17p) and/or pathogenic TP53 mutation, treated with zanubrutinib in combination with venetoclax. Ghia covers key data, highlighting promising remission rates and an increased depth of response measured over time. This interview concludes with a look to the future implications of these data, particularly on measurable residual disease-guided treatment cessation. 

During the interview, Ghia made the following key points¹:

• No new adverse events (AE) were observed, with the most common AE being diarrhea, neutropenia, and infections.
• The overall response rate was 100%.
• The complete remission rate was 48%.
• The highest rate of measurable residual disease negativity was 59%, recorded in the peripheral blood.
• At a median follow-up of 31.6 months, median progression-free survival (PFS) was not reached.
• The 12-month and 24-month estimated PFS rates were 95% and 94%, respectively.